BLLN — BillionToOne, Inc.

BillionToOne, Inc. (BLLN) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $108.4 million, an 84% increase year-over-year (YoY).
• Prenatal Revenue: $97.7 million, up 72% YoY.
• Oncology Revenue: $10.7 million, nearly five times the revenue from Q1 2025.
• Gross Margin: 73%, a 9 percentage point increase YoY.
• Operating Income: $17.8 million, with a 16% operating margin, compared to an operating loss of $2.3 million in Q1 2025.
• Adjusted EBITDA Margin: 24%.
• Net Income: $18.0 million, or $0.34 per diluted share, compared to a net loss of $4.0 million in Q1 2025.
• Cash Position: $537.5 million at the end of Q1.

2. Strategic Updates and Business Highlights

• Product Launches: Introduced Unity Confirm, a noninvasive fetal cell-based confirmation assay for high-risk NIPTs, which is expected to enhance the prenatal product portfolio.
• Test Volume Growth: Achieved a 44% YoY increase in test volume, totaling approximately 188,000 tests.
• ASP Growth: Average selling price (ASP) increased 28% YoY to $571 per test.
• In-Network Contracts: Secured contracts with Anthem and UnitedHealthcare, increasing total contracted lives to approximately 300 million in the U.S.
• Operational Efficiency: Maintained COGS at $153 per test, with a focus on reducing costs while expanding margins.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $445 million - $465 million, reflecting a growth of 48% to 52% YoY.
• Profitability: Expect to maintain a gross margin above 70% throughout the year, with continued investments in sales and product development.

4. Bad News, Challenges, or Points of Concern

• Oncology Margins: The oncology segment currently has lower margins, which may affect overall profitability as this segment grows faster.
• Market Competition: While Unity Confirm is expected to differentiate the product line, competitive pressures in the prenatal testing market remain a concern.
• True-Up Revenue: Future revenue guidance does not include true-up revenue, which may impact financial forecasts if not realized as expected.

5. Notable Q&A Insights

• Volume Contribution: The increase in revenue guidance is primarily driven by ASP growth rather than volume increases, with expectations for sequential growth in Q2 and Q3 but a slower Q4 due to seasonality.
• Sustainability of Margins: Management expressed confidence in sustaining gross margins above 70%, despite potential quarterly volatility.
• Unity Confirm Market Size: Estimated that Unity Confirm will only serve about 0.5% to 1% of patients testing positive on cell-free DNA tests, emphasizing its role as a follow-up rather than a frontline test.
• MRD Launch: The tumor-naive MRD test is on track, with expectations for significant adoption among community oncologists once launched.
• Health System Adoption: The timeline for health system adoptions is variable and not directly embedded in guidance, but ongoing efforts are being made.

This summary encapsulates the key points from the earnings call, highlighting both the strong performance and the challenges faced by BillionToOne, Inc. as they navigate a competitive landscape in molecular diagnostics.